There is reasonable evidence from prospective epidemiological studies which suggests that cannabis use can precipitate schizophrenia in persons who are vulnerable because of a personal or family history of schizophrenia. There is also evidence that a genetic vulnerability to psychosis increases the risk that cannabis users will develop psychosis (McGuire et al., 1995; Arseneault et al., 2002; Verdoux et al., 2002). A casual relationship also has biological plausibility in that the cannabinoid and dopaminergic neurotransmitter systems interact in animals. D'Souza and colleagues (1999) have shown in a provocation study that THC produces a dose-dependent increase in psychotic symptoms under double-blind placebo conditions; and Caspi and colleagues (2005) have shown an interaction between specific alleles of the COMT allele and psychotogenic effects of cannabis. If these results can be replicated and extended, they will increase the likelihood that cannabis can be a contributory cause of psychosis in vulnerable individuals.
Cannabis made another leap forward in 1964 when Israeli scientist Dr. Raphael Mechoulam identified the structure of delta-9-tetrahydrocannabinol, or THC. This discovery earned him godfather status of modern cannabis. This particular discovery allowed science to understand THC’s nature as a psychoactive compound in cannabis as well as CBD’s non-intoxicating but vastly therapeutic benefits.
Cannabis use and psychotic symptoms and disorders are associated in the general population (see, for example, Degenhardt and Hall, 2001; Tien and Anthony, 1990) and in clinical samples of patients with schizophrenia (Mueser et al., 1992; Warner et al., 1994; Hambrecht and Hafner, 1996). The major contending hypotheses to explain the association have been: (i) that cannabis use precipitates schizophrenia in persons who are otherwise vulnerable; (ii) cannabis use is a form of self-medication for schizophrenia; and (iii) that the association arises from uncontrolled residual confounding by variables that predict an increased risk of cannabis use and of schizophrenia (Macleod et al., 2004).
Karl W. Hillig, a graduate student in the laboratory of long-time Cannabis researcher Paul G. Mahlberg at Indiana University, conducted a systematic investigation of genetic, morphological, and chemotaxonomic variation among 157 Cannabis accessions of known geographic origin, including fiber, drug, and feral populations. In 2004, Hillig and Mahlberg published a chemotaxonomic analysis of cannabinoid variation in their Cannabis germplasm collection. They used gas chromatography to determine cannabinoid content and to infer allele frequencies of the gene that controls CBD and THC production within the studied populations, and concluded that the patterns of cannabinoid variation support recognition of C. sativa and C. indica as separate species, but not C. ruderalis. The authors assigned fiber/seed landraces and feral populations from Europe, Central Asia, and Turkey to C. sativa. Narrow-leaflet and wide-leaflet drug accessions, southern and eastern Asian hemp accessions, and feral Himalayan populations were assigned to C. indica. In 2005, Hillig published a genetic analysis of the same set of accessions (this paper was the first in the series, but was delayed in publication), and proposed a three-species classification, recognizing C. sativa, C. indica, and (tentatively) C. ruderalis. In his doctoral dissertation published the same year, Hillig stated that principal components analysis of phenotypic (morphological) traits failed to differentiate the putative species, but that canonical variates analysis resulted in a high degree of discrimination of the putative species and infraspecific taxa. Another paper in the series on chemotaxonomic variation in the terpenoid content of the essential oil of Cannabis revealed that several wide-leaflet drug strains in the collection had relatively high levels of certain sesquiterpene alcohols, including guaiol and isomers of eudesmol, that set them apart from the other putative taxa. Hillig concluded that the patterns of genetic, morphological, and chemotaxonomic variation support recognition of C. sativa and C. indica as separate species. He also concluded there is little support to treat C. ruderalis as a separate species from C. sativa at this time, but more research on wild and weedy populations is needed because they were underrepresented in their collection.
Furthermore, medical cannabis use is legal in many more places than recreational marijuana use. Current research, alongside patient and caregiver testimony, attests to the many medicinal applications of marijuana. From pain to serious neurological diseases, medical cannabis is emerging as a safe and viable alternative to many common prescription medications.
If you haven’t been bombarded with CBD marketing or raves about it from friends, get ready. This extract—which comes from either marijuana or its industrial cousin, hemp—is popping up everywhere. There are CBD capsules, tinctures, and liquids for vaping plus CBD-infused lotions, beauty products, snacks, coffee, and even vaginal suppositories. Already some 1,000 brands of CBD products are available in stores—and online in states that don’t have lenient cannabis laws. This is a tiny fraction of what’s to come: The CBD market is poised to exceed $1 billion by 2020, per the Chicago-based research firm Brightfield Group.
Peltz will be granted options to purchase 19.9 million common shares in the company at C$10.34 ($7.74) a share. The options will vest over a four-year period on a quarterly basis, and the vesting may accelerate if the company meet certain goals, including the consummation of certain defined transactions and the share price being at least at C$31.02 and C$41.36 for a specified number of trading days.
Newly sworn-in Colorado Gov. Jared Polis (D) delivered his State of the State address on Thursday, laying out his administration’s agenda which involves strengthening the economy with cannabis and becoming the nation’s leader in industrial hemp farming. At the beginning of the speech, Polis mentioned cannabis as one of several industries that have made Colorado’s … Continue reading Colorado Governor Touts Marijuana And Industrial Hemp In State Of The State Address
Can CBD oil help anxiety? Cannabidiol (CBD) is a chemical occurring in cannabis plants. It is possible to add CBD oil to food, and an increasing amount of evidence suggests that it may improve mental health, particularly anxiety. It does not seem to have adverse side effects, but CBD oil is illegal in some states. Learn more about CBD oil here. Read now
HempWorx CBD is short for HempWorx CBD (cannabidiol) products featuring HempWorx CBD oil and 5 additional CBD products. The HempWorx CBD oil products are full spectrum meaning they consist of many parts of the hemp plant with a host of cannabinoids rather than isolated CBD alone. Our third party lab test results show you the breakdown of the cannabinoid profile and potency. Full spectrum CBD Oil combines the powerful active ingredients of the hemp plant to create an entourage effect which has been shown to be more effective in treating conditions such as chronic pain than isolated CBD only.
Some states only allow for products infused with CBD, some only allow for high-CBD and low-THC products, while others allow both THC and CBD. To further confuse the American citizenry, some states permit patients the use of CBD, but require that they travel to another state to purchase it. To make sense of this confounding patchwork and to learn about each individual state’s CBD laws, read the Weedmaps Laws and Regulations page.
In the early 1990s, industrial hemp agriculture in North America began with the Hemp Awareness Committee at the University of Manitoba. The Committee worked with the provincial government to get research and development assistance, and was able to obtain test plot permits from the Canadian government. Their efforts led to the legalization of industrial hemp (hemp with only minute amounts of tetrahydrocannabinol) in Canada and the first harvest in 1998.
Germplasm for the improvement of hemp is vital for the future of the industry in North America. However, there are no publicly available germplasm banks housing C. sativa in North America. The hundreds of seed collections acquired for Small’s studies (reviewed in Small 1979) were destroyed in 1980 because Canadian government policy at that time envisioned no possibility that hemp would ever be developed as a legitimate crop. An inquiry regarding the 56 United States Department of Agriculture hemp germplasm collections supplied to and grown by Small and Beckstead (1973) resulted in the reply that there are no remaining hemp collections in USDA germplasm holdings, and indeed that were such to be found they would have to be destroyed. While hemp has been and still is cultivated in Asia and South America, it is basically in Europe that germplasm banks have made efforts to preserve hemp seeds. The Vavilov Institute of Plant Research in St. Petersburg, Russia has by far the largest germplasm collection of hemp of any public gene bank, with about 500 collections. Detailed information on the majority of hemp accessions of the Vavilov Institute can be found in Anon. (1975). Budgetary problems in Russia have endangered the survival of this invaluable collection, and every effort needs to be made to find new funding to preserve it. Maintenance and seed generation issues for the Vavilov hemp germplasm collection are discussed in a number of articles in the Journal of the International Hemp Association (Clarke 1998b; Lemeshev et al. 1993, 1994). The Gatersleben gene bank of Germany, the 2nd largest public gene bank in Europe, has a much smaller Cannabis collection, with less than 40 accessions (detailed information on the hemp accessions of the Gatersleben gene bank are available at fox-serv.ipk-gatersleben.de/). Because hemp is regaining its ancient status as an important crop, a number of private germplasm collections have been assembled for the breeding of cultivars as commercial ventures (de Meijer and van Soest 1992; de Meijer 1998), and of course these are available only on a restricted basis, if at all.
In the 1970s, the taxonomic classification of Cannabis took on added significance in North America. Laws prohibiting Cannabis in the United States and Canada specifically named products of C. sativa as prohibited materials. Enterprising attorneys for the defense in a few drug busts argued that the seized Cannabis material may not have been C. sativa, and was therefore not prohibited by law. Attorneys on both sides recruited botanists to provide expert testimony. Among those testifying for the prosecution was Dr. Ernest Small, while Dr. Richard E. Schultes and others testified for the defense. The botanists engaged in heated debate (outside of court), and both camps impugned the other's integrity. The defense attorneys were not often successful in winning their case, because the intent of the law was clear.
Queensland has allowed industrial production under licence since 2002, where the issuance is controlled under the Drugs Misuse Act 1986. New South Wales now issues licences under a law, the Hemp Industry Regulations Act 2008 (No 58), that came into effect as of 6 November 2008. Most recently, South Australia legalized industrial hemp under South Australia’s Industrial Hemp Act 2017, which commenced on 12 November 2017.
Hempworx Distributors can sell all of the other My Daily Choice products worldwide. If you like those products you may want to get started that way. This was the last PDF Hempworx distributed. If you scroll down the PDF file, near the end, you will see the timetable for reentering the EU, Canada, and Ghana. Hempworx missed the July target date to begin shipping to Canada.
Although the HempWorx ‘About Us’ page is filled with excellent information on the history of CBD, there is unfortunately little data about the actual organization itself. We did learn, however, that they use “special” supercritical technology that extracts over 400 phytonutrients from the raw hemp material, and that they don’t use any harmful solvents or heat, which is of course a good thing.
Marijuana is the most popular illicit drug in the world, for no reason other than the fact that it produces a psychoactive chemical called tetrahydrocannabinol. Still, recreational marijuana use, which involves pursuing the euphoric sensations produced by cannabis consumption, is steadily becoming more and more legal, both in the United States and abroad.
In a study with HIV-positive adult men, blood concentrations of ghrelin and other appetitive hormones (leptin, PYY, and insulin) were tested after having received smoked medicinal cannabis or matched placebo for HIV-associated neuropathic pain. Cannabis administration, as compared to placebo, significantly increased ghrelin concentrations in this study. In addition, leptin and PYY levels were, respectively, increased and decreased, but no impact on insulin levels was found (Riggs et al., 2012).
Early this month, the FDA just approved a new drug for depression called esketamine. Esketamine, marketed under the brand name Spravato, is a ketamine-based drug designed for patients who aren’t responding to conventional antidepressant medications. It comes in a nasal spray form, and is touted to be the world’s first quick-relief depression medication in the market.
^ Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM, Stadelmann AM (December 2005). "Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract". Ther Drug Monit. 27 (6): 799–810. doi:10.1097/01.ftd.0000177223.19294.5c. PMID 16306858.
The gateway effect may appear due to social factors involved in using any illegal drug. Because of the illegal status of cannabis, its consumers are likely to find themselves in situations allowing them to acquaint with individuals using or selling other illegal drugs. Utilizing this argument some studies have shown that alcohol and tobacco may additionally be regarded as gateway drugs; however, a more parsimonious explanation could be that cannabis is simply more readily available (and at an earlier age) than illegal hard drugs. In turn alcohol and tobacco are easier to obtain at an earlier point than is cannabis (though the reverse may be true in some areas), thus leading to the "gateway sequence" in those individuals since they are most likely to experiment with any drug offered.
Canadian experience with growing hemp commercially for the last 4 years has convinced many growers that it is better to use a single-purpose cultivar, seed or fiber, than a dual-purpose cultivar. The recent focus of Canadian hemp breeders has been to develop cultivars with high seed yields, low stature (to avoid channeling the plants’ energy into stalk, as is the case in fiber cultivars), early maturation (for the short growing seasons of Canada), and desirable fatty acid spectrum (especially gamma-linolenic acid).
A recent study published in The International Journal of Neurophamacologypoints to cannabidiol (CBD) as a cause of neurogenesis in the brain; specifically in the Hippocampus, an area typically associated with conscious memory and navigation. However, the researchers believe that CBD’s anxiety relief may be due to this neurogenesis in the brain. You can read our full article on the study here.
Essential (volatile) oil in hemp is quite different from hempseed oil. Examples of commercial essential oil product products are shown in Fig. 42. The essential oil is a mixture of volatile compounds, including monoterpenes, sesquiterpenes, and other terpenoid-like compounds that are manufactured in the same epidermal glands in which the resin of Cannabis is synthesized (Meier and Mediavilla 1998). Yields are very small—about 10 L/ha (Mediavilla and Steinemann 1997), so essential oil of C. sativa is expensive, and today is simply a novelty. Essential oil of different strains varies considerably in odor, and this may have economic importance in imparting a scent to cosmetics, shampoos, soaps, creams, oils, perfumes, and foodstuffs. Switzerland has been a center for the production of essential oil for the commercial market. Narcotic strains tend to be more attractive in odor than fiber strains, and because they produce much higher numbers of flowers than fiber strains, and the (female) floral parts provide most of the essential oil, narcotic strains are naturally adapted to essential oil production. Switzerland has permitted strains with higher THC content to be grown than is allowed in other parts of the world, giving the country an advantage with respect to the essential oil market. However, essential oil in the marketplace has often been produced from low-THC Cannabis, and the THC content of essential oil obtained by steam distillation can be quite low, producing a product satisfying the needs for very low THC levels in food and other commercial goods. The composition of extracted essential oil is quite different from the volatiles released around the fresh plant (particularly limonene and alpha-pinene), so that a pleasant odor of the living plant is not necessarily indicative of a pleasant-smelling essential oil. Essential oil has been produced in Canada by Gen-X Research Inc., Regina. The world market for hemp essential oil is very limited at present, and probably also has limited growth potential.
The self-medication hypothesis was not supported in either the van Os or Henquet studies. Both studies found that early psychotic symptoms did not predict an increased risk of using cannabis (as is required by the self-medication hypothesis). The direction of the relationships was from early cannabis use to psychosis. Their negative results have recently been supported by Verdoux et al. (2002), who examined the temporal relationship between cannabis use and psychotic symptoms using an experience sampling method. They asked 79 college students to report on their drug use and experience of psychotic symptoms at randomly selected time points, several times each day over 7 consecutive days. The sample included high cannabis users (n = 41) and an over-representation of students identified as vulnerable to psychosis (n = 16). Verdoux and colleagues found that in time periods when cannabis was used, users reported more unusual perceptions, and these relationships were stronger in vulnerable individuals. There was no temporal relationship between reporting unusual experiences and using cannabis use, as would be predicted by the self-medication hypothesis.
What is clear, though, is the DEA’s classification of all cannabis extracts as Schedule 1 controlled substances. Even as more states “legalize it,” all forms of cannabis are still illegal under federal law. And that’s a problem for HempWorx distributors who have to move product. As the DEA spokeswoman told the Port City Daily news site in North Carolina, where marijuana is illegal but decriminalized: “The plant, for human consumption, is illegal, bottom line. If you ship it — then that’s interstate commerce, that’s trafficking, and so that’s a problem.”